Scholarlink

Background <p><i>Candidozyma auris</i> is an emerging multidrug-resistant pathogen, posing challenges for infection control and management. The annual trend of <i>C. auris</i> isolation and its clinical implications for affected patients were accessed.</p> Methods <p>All adult patients with <i>C. auris</i> isolated from clinical specimens between 2022 and 2024 were included. The medical records of all the patients were retrospectively investigated.</p> Results <p>The first case of <i>C. auris</i> infection was reported in 2022. <i>C. auris</i> isolates increased from one in 2022 and 2023 to 23 in 2024. The clade analysis performed on available blood culture isolates (<i>n</i> = 6) confirmed that all analyzed isolates belonged to clade I. All patients had underlying conditions, and 20 patients (80%) had recent intensive care unit admissions. Urine was the most common source of <i>C. auris</i> (14 cases [56%]), followed by blood (six cases [24%]). Of the five patients with <i>C. auris</i> bloodstream infections and central venous catheters (CVCs), three had confirmed to have definite central line-related bloodstream infections (CRBSIs), while the remaining two had no other identifiable primary source besides the CVC. Among patients with <i>C. auris</i> in urine, one of 14 (7.1%) developed septic shock, compared with two of six (33.3%) with bloodstream isolates. The 14- and 30-day mortality rates were 24% (6/25) and 32% (8/25), respectively. The mortality rate attributable to <i>C. auris</i> isolation was 8% (2/25). The two deceased patients had CRBSI caused by <i>C. auris</i>.</p> Conclusions <p>All <i>C. auris</i> isolates identified from blood cultures belonged to clade I. The isolation rate of <i>C. auris</i> is showing an increasing trend. Bloodstream infections caused by <i>C. auris</i> predominantly occurred in patients with CVCs and were associated with higher attributable mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical implications in patients with isolation of Candidozyma auris in a single tertiary hospital

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月14日

查看全文
  • Taewoo Kim,
  • Young Jin Kim,
  • Yu-Mi Lee

摘要

Background

Candidozyma auris is an emerging multidrug-resistant pathogen, posing challenges for infection control and management. The annual trend of C. auris isolation and its clinical implications for affected patients were accessed.

Methods

All adult patients with C. auris isolated from clinical specimens between 2022 and 2024 were included. The medical records of all the patients were retrospectively investigated.

Results

The first case of C. auris infection was reported in 2022. C. auris isolates increased from one in 2022 and 2023 to 23 in 2024. The clade analysis performed on available blood culture isolates (n = 6) confirmed that all analyzed isolates belonged to clade I. All patients had underlying conditions, and 20 patients (80%) had recent intensive care unit admissions. Urine was the most common source of C. auris (14 cases [56%]), followed by blood (six cases [24%]). Of the five patients with C. auris bloodstream infections and central venous catheters (CVCs), three had confirmed to have definite central line-related bloodstream infections (CRBSIs), while the remaining two had no other identifiable primary source besides the CVC. Among patients with C. auris in urine, one of 14 (7.1%) developed septic shock, compared with two of six (33.3%) with bloodstream isolates. The 14- and 30-day mortality rates were 24% (6/25) and 32% (8/25), respectively. The mortality rate attributable to C. auris isolation was 8% (2/25). The two deceased patients had CRBSI caused by C. auris.

Conclusions

All C. auris isolates identified from blood cultures belonged to clade I. The isolation rate of C. auris is showing an increasing trend. Bloodstream infections caused by C. auris predominantly occurred in patients with CVCs and were associated with higher attributable mortality.